ClinicalTrials.gg
RecruitingNCT05044273IRIS SynergyXDUpdated Dec 29, 2025

Evaluation of Effectiveness and Safety of Synergy XD and Synergy Megatron™ Stent

An observational study in Coronary Artery Disease, Cardiovascular Diseases and Heart Diseases, sponsored by Jung-min Ahn. Recruiting at 23 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Jung-min Ahn · Observational

How we know

From the registry’s dates

  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 361 studies in Coronary Artery Disease with a site in Korea, Republic of — 81 open to participants now, 103 under way, 2 of them phase 3. Coronary Artery Disease · Korea, Republic of.

Planned enrollment
56th of 152
2,000 · median 1,113
Started
2022
with 24 others
Observational
153 of 361
40 open now
Primary completion
2026-12
later than 31 of 102 live
Registered
262nd of 361
by date

Among the 361 studies in Coronary Artery Disease with a site in Korea, Republic of, this one is the 56th largest by planned enrollment of the 152 observational ones that give a count, is one of 25 that started in 2022, is one of 153 observational ones, reaches primary completion later than 31 of the 102 other live ones, and was the 262nd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

81 of the 361 studies in Coronary Artery Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

76 more — sign in →

All 81 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 19 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 361 studies in Coronary Artery Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the effectiveness and safety of Synergy XD stent and Synergy Megatron™ Stent in the "real world" daily practice as compared with the other drug-eluting stents.

Read the detailed description

This study is a non-randomized, prospective, open-label registry to compare the effectiveness and safety of Synergy XD stent and Synergy Megatron™ Stents versus other drug-eluting stents (DES) in patients with coronary artery disease.

03

Conditions studied

  • Coronary Artery Disease
  • Cardiovascular Diseases
  • Heart Diseases
  • Myocardial Ischemia
  • Coronary Disease

Keywords

  • drug eluting stent
  • percutaneous coronary intervention
  • real world
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients with Synergy XD stent or Synergy Megatron™ stent

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 19 years old
  • Patients receiving Synergy XD stent(s) or Synergy Megatron™ stent(s).
  • The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.

Exclusion criteria

Exclusion Criteria:

  • Patients with a mixture of other drug-eluting stents (DESs)
  • Terminal illness with life-expectancy ≤1 year.
  • Patients with cardiogenic shock
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Coronary Artery Disease

    Device: Synergy XD stent or Synergy Megatron™ Stent

Interventions

  • DeviceSynergy XD stent or Synergy Megatron™ Stent

    Percutaneous coronary intervention with Synergy XD stent or Synergy Megatron™ Stent

06

What researchers measure

Primary outcomes

  1. The composite event rate of death, non-fatal myocardial infarction, or target vessel revascularization

    A composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event that is considered to have occurred if any one of several different events is observed.

    Time frame: 1 year

Secondary outcomes

  1. The event rate of all death

    Time frame: 5-year

  2. The event rate of cardiac death

    Time frame: 5-year

  3. The event rate of myocardial infarction

    Time frame: 5-year

  4. The composite event rate of death or myocardial infarction

    Time frame: 5-year

  5. The composite event rate of cardiac death or myocardial infarction

    Time frame: 5-year

  6. The event rate of target-vessel revascularization

    Time frame: 5-year

  7. The event rate of target-lesion revascularization

    Time frame: 5-year

  8. The event rate of stent thrombosis

    According to Academic Research Consortium(ARC) criteria

    Time frame: 5-year

  9. The event rate of stroke

    Time frame: 5-year

  10. The event rate of procedural success

    Defined as achievement of final diameter stenosis of \<30% by visual estimation, without the occurrence of death, Q-wave myocardial infarction, or urgent revascularization during the index hospitalization.

    Time frame: 3 days

07

Study locations

19 of 23 sites recruiting
  • Hallym University Medical Center
    Anyang, South Korea
    Recruiting
    • Sang-ho Choi, MD · Contact
    • Sang-ho Choi, MD · Principal investigator
  • Dong-A University Hospital
    Busan, South Korea
    Recruiting
    • Yong-rak Cho, MD · Contact
    • Yong-rak Cho, MD · Principal investigator
  • Inje University Busan Paik Hospital
    Busan, South Korea
    Terminated

    Not enrolling at this site — choose another above.

  • Inje university Pusan Paik hospital
    Busan, South Korea
    Recruiting
    • Tae-hyun Yang, MD · Contact
    • Tae-hyun Yang, MD · Principal investigator
  • Pusan National University Hospital
    Busan, South Korea
    Terminated

    Not enrolling at this site — choose another above.

  • Pusan National University Hospital
    Busan, South Korea
    Recruiting
    • Jeong-cheon Choi, MD · Contact
    • Jeong-cheon Choi, MD · Principal investigator
  • Pusan National University Yangsan Hospital
    Busan, South Korea
    Recruiting
    • Min-gu Cheon, MD · Contact
    • Min-gu Cheon, MD · Principal investigator
  • Gyeongsang National University Changwon Hospital
    Changwon, South Korea
    Recruiting
    • Jae-seok Bae, MD · Contact
    • Jae-seok Bae, MD · Principal investigator
  • Samsung Changwon Hospital
    Changwon, South Korea
    Recruiting
    • Yong-hwan Park, MD · Contact
    • Yong-hwan Park, MD · Principal investigator
  • Keimyung University Dongsan Medical Center
    Daegu, South Korea
    Recruiting
    • Chul Hyun Lee, MD · Contact
    • Chul Hyun Lee, MD · Principal investigator
  • Veterans Hospital
    Daegu, South Korea
    Recruiting
    • Sang-wook Kang, MD · Contact
    • Sang-wook Kang, MD · Principal investigator
  • Yeungnam University Medical Center
    Daegu, South Korea
    Recruiting
    • Woong Kim, MD · Contact
    • Woong Kim, MD · Principal investigator
  • Gangneung Asan Hospital
    Gangneung, South Korea
    Recruiting
    • Han-bit Park, MD · Contact
    • Han-bit Park, MD · Principal investigator
  • Chonnam National University Hospital
    Gwangju, South Korea
    Recruiting
    • Min-cheol Kim, MD · Contact
    • Min-cheol Kim, MD · Principal investigator
  • Wonkwang University Hospital
    Iksan, South Korea
    Recruiting
    • Kyung Ho Yoon, MD · Contact
    • Kyung Ho Yoon, MD · Principal investigator
  • CHA Bundang Medical Center, CHA University
    Seongnam, South Korea
    Terminated

    Not enrolling at this site — choose another above.

  • Seoul university Bundang hospital
    Seongnam, South Korea
    Recruiting
    • Jung-won Suh, MD · Contactsuhjw1@gmail.com
    • Jung-won Suh, MD · Principal investigator
  • Asan Medical Center
    Seoul, South Korea
    Recruiting
    • Jung-min Ahn, MD · Contact
    • Jung-min Ahn, MD · Principal investigator
  • Hanyang University Seoul Hospital
    Seoul, South Korea
    Recruiting
    • Young-hyo Lim, MD · Contact
    • Young-hyo Lim, MD · Principal investigator
  • Korea University Anam Hospital
    Seoul, South Korea
    Recruiting
    • Jae-hyung Park, MD · Contact
    • Jae-hyung Park, MD · Principal investigator
  • Korea University Guro Hospital
    Seoul, South Korea
    Terminated

    Not enrolling at this site — choose another above.

  • The Catholic University of Korea, ST. Vincent's Hospital
    Suwon, South Korea
    Recruiting
    • Sung-ho Hur, MD · Contact
    • Sung-ho Hur, MD · Principal investigator
  • Ulsan University Hospital
    Ulsan, South Korea
    Recruiting
    • Kyung-min Park, MD · Contact
    • Kyung-min Park, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Dec 2026, 51 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 51 months is close to that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2021
First posted
Sep 14, 2021
StartActual
Sep 1, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2031
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05044273
Lead sponsor
Jung-min Ahn
Collaborators
CardioVascular Research Foundation, Korea
Responsible party
Jung-min Ahn (Assistant professor of Medicine, Division of Cardiology, Department of Internal Medicine, Asan Medical Center) — Sponsor-investigator
First posted
Sep 14, 2021
Start date
Sep 1, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Dec 29, 2025

Study contacts

Jung-hee Ham, Project Manager
Contact
cvcrc5@amc.seoul.kr
82230104728

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion